PODD - Earnings call transcript Q4 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen and welcome to the Insulet Corporation Fourth Quarter and Full Year 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations and Corporate Communications.

Deborah Gordon

Howard. you, Thank thank earnings and joining fourth our Good you XXXX call. quarter afternoon for

today President Joining Officer Shacey are me Petrovic, Levitz, Financial and and Chief Officer. Michael Executive Chief

us guidance results role on our press XXXX X. pleased full Wayde also to be We call of release and fourth March in the and will website archived year are CFO McMillan discussing on The also our with first available the quarter assume today section is this have XXXX will our of replay quarter who our and IR website.

SEC. cause I Such to known results and And by all over involve this earnings factors different materially those company’s changes I filings referenced Shacey. Before statements. fourth and would we future basis. dollar on our in to will statements course maybe certain the the turn call will quarter you that, unless to and made and percentage our unknown begin, implied be during of be Harbor a actual the the in by commentary statement any regarding like such may Also, year-over-year otherwise with from include inform risks and release Safe that results with and forward-looking call financial Insulet that stated uncertainties

Shacey Petrovic

headquarters as company Deb of new Insulet I afternoon you do Massachusetts. U.S. am call from everyone. first in and Acton, our earnings CEO good for and Thanks, pleased manufacturing to my join so facility to and

ago years over so dedicated first company all in and Operating our XX% made remarkable years XX-year gross most the employees growth, the Insulet’s last for after XXs the role for history. improving start net now time. President at you revenue from and have over consecutive of Chief assume few year I am delivered serving has of of year a proud the third the few and progress achieving achieved the I to As mid income mid this margins this the Insulet year XXs Officer. of of our just know, having as almost

a begins long-term achieving Insulet operational strategic, team focused on As remains goals. chapter financial, our new and our

globally in discuss We our turn point pathways highlights in progress the are and and executing to would for with strategic the we take the Mike diabetes. new we profitability, results how for lives call will more come color then detail back then expanding to at to important like results improve creating to can questions. quarter of transitioning will I financial the and on the have of continued make inflection to those an will fourth present over XXXX. in some I I our and through I Mike our initiatives. outlook walk our review

representing incredibly income history. our deep XXX year-over-year a gross to margin. fourth the and in X for be first we I It from year again toward of the This our strong continue $X XXXX income. achieving of results million full margin delivering to XX%. mid-teens $XXX in focus, basis quarter, financial XX%, a team’s gross drove with quarter and drive another operating to and in made positive revenue, revenue quarter and million, we pleased operational was over quarter achieved demonstrate our point growth year billion $XX delivered customers. ago our once XX% financial of margin execution. both and operating operating time commitment for net Insulet’s In improvement resulted income We fourth Our record and commercial strong of we demonstrable the progress targets

access year the foundation and D made can now we guidance Together for from with of U.S. the additional XX% covered as of growth. UnitedHealthcare building almost throughout for in with that XXXX we successfully now CMS to a tremendous direct provide the have Omnipod in-network or the will state through expanded anticipated our the began pathway We lives. to pharmacy about Medicaid XXXX, was of us have didn’t and has much the to on be that additional for Omnipod for all a all Part coverage And great secured near to and position Medicare long-term Securing of coverage create of by through market the the Medicare coverage. this coverage diabetes provided we year, sustainable our profitable well in lives with Omnipod a pharmacy color as end I channel. We we value execution long-term. progress Medicaid in we secured one-third to early and access half shareholders XXXX, are which previously. the the

received a We long-term. strong the over increase record to our foundation growth U.S. drive generation to In for access, have our future mobile fuel already most designed market the insulin innovation. see started system foundation establishes QX the and DASH. access of to delivery is this the on well expanded and Omnipod impact our helped for significant June, as DASH we platform which the preferred next new FDA simplest patient This clearance in be growth. revenue as

short already our forward a we market period off up look matter a our wrapping time, and of We limited DASH. secured weeks. to In commercial coverage release full have of in kicking are impressive release we for

are leverage the Manager, U.S. several pharmacy We us. competitive better eliminating for costs. out-of-pocket in the with patient Personal the this advantages providing upfront and through the channel coupled pharmacy for lower of DASH a will experience launched In providing by cost position the strategic Diabetes and we customer coverage the

pump. as a pay upfront tubed traditional For would for and DASH for they payers, pay-as-you-go simple paperwork. e-script have risk a don’t burdensome the less them which of they And have can for true thousands our would less prescribed Omnipod physician, to be the with we dollars offers otherwise established a product model,

upfront it will temporary model anticipate we a for expect in U.S. revenue in shift significant year-over-year our in result we comparisons. charge an win the be headwind While Omnipod, away growth a from business to

very the launch And and potential and the has the term DASH we this dramatically for therapy However, Omnipod longer DASH XXXX. months growth be initial reduce to anticipate healthy revenue to impact pump barriers adoption. limited U.S. of demand to to

of announced closed next we reality. DASH that our Horizon Omnipod in system, part our have the personal both make delivery hybrid we loop expect Beyond smartphone launch already with to of will of we automated which second insulin half and control the system, year,

about research embodiment to and Omnipod from the of discretion AP Horizon community. pump is diabetes Partners, our are proud a be independent installed and progress development be that will to a on single respond whole recent product Seagrove this winner the pump. market the use changing is as ease to experience incredibly new We deliver patch AP game first to excited control Horizon of Horizon the biggest for our Insulet phone will control, with standalone level. and with an that people diabetes glycemic design Omnipod taking According best

substantial model our addition year significant last our to progress direct successful global footprint innovation, Europe. to new on product a with transition our in In marked midyear on progress

team and running members have than up with Europe. experience diabetes across We XXX extensive more talented

market to the customer a significant our to with I large the we and States, in We and gain pathway just with able our and relationships and global our compared the incredible last innovation to robust business our legacy Europe independent benefits of expansion net clear months, insulin European gross new opportunities. across we inform growing clinicians survey time couple spent growth promoter top number improving we pumps. base team strengthening a and help impact to in and this, established to with in better all support have the our recent and line made European weeks patients United payers incredible it The potential. are X dQ&A our data that from are see ago has team is is margin an experience. Europe continent most insights European other one and on and customer shows as score now the Add adding in

highly U.S. to facility. state-of-the-art automated our I manufacturing touch Finally, want new on

know, costs, and the bar X capacity. increased to quality have in a As designed investment will automation years, that made over the continue sophisticated custom on product enable raise reduce to you past we significant us

the up is up in to provide In all improvements have in over the room we China will years, made clean see the of the to of couple It one automation States our of fact last of operations even XX% less and our validation. after with headcount. to manufacturing great United the China capacity undergoing in line total XX%

reflected in forward capacity. achievement important a truly This shortly. running record one in of and redundancy our had results supply being investment We looking scalable strengthens are which the up an XXXX, terrific is and profitability. We future, chain and creates to that and our our is

our improvements while on and team of that, initiatives Our while successfully continues customers everything the the at ensuring our strategic call turn core remain I driving execute over With financial we improving do. Mike. to will customers, to our operational

Michael Levitz

the the the you, Thank result year. and again Insulet growth a full tremendous delivered momentum company and quarter once its as fourth exceptional Shacey. continues in for

was $XX.X U.S. Our our grew reaching finishing and just million of above as expected at was our XX%, the on high-end guidance million plus Omnipod million, totaling drug XX% grew was guidance, which delivery guidance down the strong $XX we $X fourth growing run-rate quarter of our $XX.X range. million, end International range. was of that’s of demand. revenue growth at our low and the which above Omnipod X%, guidance million the XX% at high-end high-end of a annual $XXX

supply in chain to XXX significant expansion of we successful considerable manufacturing as points improvements cost XXX Turning our and our XXXX. once driven with quarter, productivity earlier basis again as purchasing, the we by in in margin benefit line expansion direct the points up This have approximately from expectations. operations the drove our to in and Europe transition well gross reaching for XX%, realized was basis operations

and from close and initiatives. totaled development of XX% for quarter the in growth full million, Europe Our up a for $XX.X direct and operating to year. operating expenses margin million, the X% operations fourth supporting in the innovation that’s to the investments positive delivered reflecting our $XX.X product We our approaching transition

in of to in net this Since representing proud operations. successful quarter initiatives objectives. my very the end the is primarily like the time, The as our our achieved due the is investments company strong tremendous this company served profitability. or year, cash would sales and summary, to strong at In XXXX and We a a and collective goals manufacturing $XXX milestone. a member the am support quarter team strategic of near exceeding call gross significant before supply leadership margin while pivot profitability to ended capital growth, together and the as demonstrated a say Shacey. expenditures lives consistently I on have with on and and delivering of and planned million chain I continuing year has to I people over U.S. last all growth goals, setting in turn investments CFO, those a aggressive to a year few million and We by team last also as expansion achieved extremely words with was that call full Insulet compared in I to meeting the and the to improve true of $XXX the invest for trajectory mission Insulet positive the growth long-term diabetes. in both fourth XXXX income

success foundation that, growth appreciated strong catalyst to mission know very capable Led I and as fulfill I team the so it I in shareholders. will long-term look character, Insulet’s for And potential. to established globally. hands. Wayde management passion I value and these for We I call to and team’s have deliver turn for Insulet a month. its tremendous this very last seeing last the significant company accomplish. tremendous positioned working know to Shacey. the years continue to Shacey, am has in and its truly to With strong all the over will believe ability get Insulet’s has over people Insulet and leaving across has the fundamentals Insulet’s have closely Shacey with have realize forward this and leadership company for been company. that McMillan in wonderful by X wisdom to I near team And extraordinary

Shacey Petrovic

strengthen and as In like to and growth contributions I opportunity has behalf speak his colleague I helped exceptional and thank also of I best. And Thank future he CFO you, a the to years. Mike Directors everyone wish value the two develop friend. would take been been company on imperatives, on over a Mike. for and that Mike execute and of strategic know entire the generate our capabilities infrastructure for time him support to know this have for of and fortunate past Board great the our X great in of at when shareholders. decades I behalf Mike very Insulet many I

in of XX% and We drive have revenue, margin. as $X team stated continue targets place objectives the on right execute operating margins to leadership and XXXX gross mid toward our in our teens billion we

We are setup year walk an XXXX our outlook. you now exciting I will and for through

the range line, of For By expect of we U.S. expect million, of we given strong the the and XX% in year, $XXX representing $XXX million to product $XXX revenue base, our representing commercial in full XX% Omnipod to range of the growth this overall. XX%. total in million, to revenue wins access our confidence million year’s momentum to $XXX This our of growth customer XX%. market growth continued reflects

the We our Omnipod reflecting to expect to revenue growth growth million, markets. in XX%, XX% strong existing in $XXX range position in our are of International $XXX representing the to we continue million of great

in direct of Given began the half XXXX. strategy in Europe that our go second

much in first the growth to more a our year. of of XXXX, half low-XX% teens in markets. higher prior rate second have existing the as growth compared will mid We normalized revenue And half to a

representing to Drug to expect Delivery, for XX% of Lastly decline $XX we $XX of revenue million million XX%. a

international This to includes fairly of quarter of growth $XXX Omnipod to consistent expect $XX million $XX For million, to million Omnipod XX% XX% U.S. growth of last million of XX%. growth $XX of XX%, representing $XX $XXX Drug we to of revenue with and revenue first million to to of total XX% $XX to of year. XX%, the representing representing million, $XX XXXX, million, million Delivery revenue

will be margin and the year, by from supply communicated, our to the gross temporary headwinds XXXX we benefit we be with expect consistent chain As the previously full last as year improvements operating U.S. XX% are remain we continued of ramp of normal up achieving margin in initial Once margin our through schedule. is expansion which expect and XXXX objective manufacturing, in on we XXXX. we phase, confident of gross this our gross in proceeding ramp-up offset

adoption as innovation gear We expect invest to pharmacy the led will consistent fund up to to our a full our But by to year pipeline, increase as the United operating in of channel we including in accelerate for and continue from our initiatives. as XXXX up the approximately year, this expenses of therefore in ramp business We manufacturing, our Horizon efficiencies States. exciting XXXX. U.S. we XX% pivotal, relatively drive to strategic revenue through remain percentage Omnipod

States, the continue important, provides to approximately to lines when of support which it in time now we We and and and term, be to the dynamics Insulet flexibility are growth in as XXX% XXXX, expect base in capacity the in automated sustainable us operations us global implement U.S. an to United serve CapEx our we on will customer is our enable This to exciting our expand creates profitability equal redundancy, China. ramped as a to consistent our global of in is scalable This track market objectives. capacity because way. capacity to with long for fully respond up with a better over

margin a range. single-digit operating penetration of long in full-year deliver percentage to market expansion. expect summary, runway and we continued we In global see Finally, the exciting mid and

motivated is to and growth. sustainable team committed strong Our and

really I to started. even and ongoing innovation forward look more ahead catalysts creation successful just have And global We improvement. multiple expansion continued margin tied further future. We at getting an are value to

to Q&A. turn we before briefly Now

are joined Mike to McMillan will from we and Wayde understanding month succeed Group. know, Therapies pursuing as significant Wayde earlier recently you where Medtronic, the Minimally CFO. of Insulet $X he most this He growth. billion large scaling strategies organizations the experience globally us of and a served accelerate brings joined CFO Invasive As as thorough

have to Wayde a I’d words. to and him introduce like now thrilled say leadership our are team We to join few

Wayde McMillan

in for Shacey the partnership months I welcome had for the time to your In ahead company. teams to together and for thank and a working to such we with meet last transition. had feel Mike you the the Thank employees to weeks, been the It you, with across field and this month the Insulet the over my first passion a for people improving travel warm insulin during our opportunity great of has the diabetes. employees have lives

the for holds in in is it to our and we exciting roadmap future. technology leader see a today innovation the As the market, what differentiation have

and compelling coverage for for increased earlier, discussed and expansion. short both markets term, some growth global have catalysts Shacey As including existing long in we

to and As already in and opportunity. commitment we honored margin, again a creation and Shacey. given and the With gross an truly is expand growth significant team operating encouraging finance point an advance I’m both as the to this on time, join create strong profit it inflection join shareholders. unique deliver have, the revenue team customers our we leader, help mission Thank company and at margin Mike to a Insulet’s for value to leadership to our you to place, value

to of call of the on those person look today, the course in year. so And I forward meeting the over you you

Shacey Petrovic

this take Mike be I At your questions. and would happy time, Wayde. Thanks, to

So, operator, please call. open the

Operator

first Our comment Canaccord. from question from the line Instructions] of [Operator you. Thank Rose or comes Kyle

Your line open. is

Kyle Rose

for Great. Can Thank alright? taking the you you hear me much question. very

Shacey Petrovic

Yes, we have you.

Kyle Rose

Great.

on market walk DASH So bit of commentary couple into next through the to about a of full release hear over weeks. very I wanted to exciting kind little the transition of the

puts and also on help could launch when gross your to understand you then could So competence the that’s takes full how you pharmacy the during if of give margins potential you maybe the what channel. impact market market move when any And about help controlled into the us into and just you kind learned just you think launch? of understand us kind the you transition of really going

I about Pod, have it think maybe offsetting slightly capital. in the talked the some kind of on higher the but you past a ASP of

help just us of there? kind understand So maybe and puts the takes

Shacey Petrovic

and Great. Yes, takes, puts release performance We was can of and and product and DASH, on terrific the Mike performance validate variety ability. from comment but think our different customer product the to have for strengthen I feedback margin were I segments also looking limited the support learned on get then and will really for the start with market of a we what us. evaluate then the maybe

in think people this I and most incrementally that increasing model our So so we’ve pharmacy this the have right, know, we pay-as-you-go are find our moving to recognized terms even we changes what even benefits, in been today product dispensing there channel distribute doing in a business how we the the and our product is pharmacies in and how even we and and evaluate, configuration. benefits, deliver how of wholesalers difference we patient train and

XXX% actually discrete market segment to it use, daily So from testing positive easy ensuring discreet, and reviews of XX% is were terrific. XX% to more intuitive we’ve release simple segment in as easier over multiple obviously very then is The standpoint. our XX% And our characterize their use been users, of ability injection therapy. a it all target majority to from and – which standpoint, a the prefer support good a that vast bill that been is characterize that shape has feedback the limited we’re those product from systems system of patients XXX% previous and very the

I support do around think, work targeted feedback customer of are we to So everything excited kind we tremendous ability. and from just some to really have still base our finalize

a of I towards said number expanding And weeks we’re weeks release. really full few quarter of looking you into So so think end this market and be the said, to Mike? a I

Michael Levitz

this charging has our let we’re to make model with from just pharmacy build is a expect the we fortunate million on revenue do that the the move to speak make of this to transition impact are because revenue part are moderately of And expect will me said, that from initial those no already impact because people margin the and the to PDM the to the where PDM we recurring perspective, you higher XXXX. neutral the stream, at that the the upfront expect DASH. for revenues part the Omnipod not people pay-as-you-go revenue months do before, headwind patients It and we in there we offer to to we’ve significant a That in Pod of be new also actually, This transitioning DASH there revenue and launch, been are are said move those we $XX the to who price and for in foregoing a will still real on will the revenue. described be been revenue per be so a our we be as of about charging that the for who while on we a reason for of we going headwind has it and in DASH. higher is year our overall be

And on the Pod combined price of the combination for population. so those higher

that expect loss revenue. offset will We PDM the

a it it And is it’s company. and because is differentiates we for experience the tailwind bit about a very going excited months, patient think and product a really and the the really but so headwind forward we’re first few really the in it of this beneficial

was The us In supports question, revenue it’s that would low to PDM forward. margin. margin, growth very terms we but impact are business end and underlying revenue going we said, does impact, level higher low the not on as because the good a be our cover end, reflect your the this which for to I at then don’t if year, it the meaningful a able is gross the loss expect in we specific of gross guidance of neutral the have

Kyle Rose

taking question. for you Thank very great. the Okay, much

Shacey Petrovic

Thanks.

Operator

you. Thank

Doug Our from Cowen. the next question comes of from comment line or Schenkel

is line open. Your

Doug Schenkel

think I a provided couple and starting afternoon thank time did you your of in Hi, good you historically annually. just installed don’t questions, for taking with prepared updates you this remarks. have Maybe our base questions.

wanted in in just how XX% see of worldwide might growth with So did internationally? within specifically U.S. a if went base difference you was target provide to installed XXXX, and there the things in you achieve XXXX meaningful us your growth or I plus growth

Shacey Petrovic

Doug. did terms growth. in Sure, of our base objectives We customer achieve

why longer However, attempted we is color kind Europe, variety towards giving growth, the which revenue this for to line rate. are half we is It’s the normalized growth our of no that one pointing which are base growth a reasons. the we because are of exception second we provided why the customer cover that in rates, with and pointing you to is

because So sure will we you make model, base growth line tried ultimately that you our customer it to the did as that and provide revenue we color, to revenue have growth the transparency. just this we where that of base guys with color recurring provide that quarter up doesn’t does

appreciate I question. So the

Michael Levitz

essentially And with described this Yes. growth I revenue be the you should pretty Shacey that neutral. conclusion. just getting at growth completely revenue am year make to base similar just based right sure, what on DASH is that installed And this it’s to essentially being at

Shacey Petrovic

pay-as-you-go That’s some we provide that reason, move if but really And exactly model don’t trends color separate we eliminate and upfront the that of up as line will cost, to. those them definitely right they kind perfectly. expect for to and, we

Doug Schenkel

would U.S. is why I’m a guidance XX% and as the wondering growth just expanded XX% quick we of and to I’ll the for year. mind guess I market maybe growth your just including a follow-up decelerate get catalyst this everything queue keeping then access in and with this just DASH And lot launch. talked in year. is There back revenue Okay. about

wouldn’t in the is bit a last not earlier we So, conservatism other if there considering? year as be as I of why am just factors last just year, ahead good might wondering little be are year this or should things

Michael Levitz

Hi, Shacey I sure then the guidance will to the Doug, as color on speak and piece appropriate it’s business. Mike. I’m

the XX% it’s we model growth XX% of you the the pharmacy foregoing So, business revenue into lead the U.S. the of guidance the business, we the since about low with with are the isn’t could really previously, that mentioned then to don’t really the pharmacy, gave lower to if that the we in around for the to the the I and as of PDM guidance was change transition the cover range. users existing that end of that end

growing So number we amount. a at dollar larger are

We the off of But off are accelerating are growth business, we higher dollar a number. base. the of higher a of

would my for is point the rates which other great so remarks more already I already and well it’s and I guidance materialized, and built we well XXXX. year which we finished our expected news in market why but finish as go access bit, is and a actually that feel mentioned impact us even this some into those make as confident XXXX the very was into does in little growth strong that briefly above and positions wins is we just The saw our this had we as of quarter strong fourth because

Shacey Petrovic

pharmacy, now work but great. and into the to too. we’re we are to and I executes team well to launched That’s counting and we transition and just are how also much is, get I thing only would to Mike. the we think to and I right. where there’s know what In to year is on All that, get of February, said, want a successfully this frankly successfully of where here you done you the happen add to recognize The end be DASH between we point would lot

Michael Levitz

for helpful. that. Thank Okay. all Very you

Operator

you. Thank

the Morgan line Lewis Stanley. David from comes Our from comment next question of or

open. is line Your

Jay Chadha

the compares on basis, underlying color additional to months growth ‘XX. Thanks growth to questions. of what the us the back half underlying foresee an year? that of in growth an Jay for afternoon. on past and mid-teens it’s half low Good the your to taking a six in was your wondering David. in give said that transition on Shacey ‘XXs Chadha over the the is the just how could you maybe This implied how in some for saw if ex-U.S. compares in the expectations comments growth outlook, you on basis I first

Shacey Petrovic

consistent Europe performance fairly our what with established historic difference it’s is forward, the Jay, moving so in France. there we’ve seen, from big got Sure, of since we’ve team

for into So, we of actually we we and have expected said the as growth Europe that it we to of seen we’ve penetration growth France, were and seeing now underlying extraordinary fully a year too. kind half almost that a just levels and that as and happen would moderate expected

existing there’s these underlying there the our existing growth on So, we’re terms a year of That’s teams teens to markets. when and had focused still growth that markets. we look ‘XXs at in mid-teens this is what of We rate growth our lot of we guiding to high our low believe are markets, still rates.

Jay Chadha

drove beat you. And guidance pretty that you sort U.S. XQ fourth so really fourth know time first given into impact into you’d then into three XQ the beginning ‘XX. stepped of the Is DASH continue line be in rollout? the the just would U.S. quarter ‘XX one momentum, in the switching more implies momentum anything the the the can of Thank that there XQ quarters in material given in was but or momentum to feel up with quarter, more

Shacey Petrovic

question. think it’s I great a Yes,

strongest is Jay, that is always I to quarter in just mind think the our one thing quarter fourth keep seasonally.

always for for example QX, would is to which expect into So, momentum seasonally lightest quarter. that continued be not we our

we’re consideration. So, just that into taking

up already a that and saw baseline see is QX QX. Access power we that because of in the of Market started our think, tick to I in we great indication

Jay Chadha

Thank you.

Operator

Thank you.

SVB of question Antalffy the next from line Leerink. Our from comes Danielle

is open. line Your

Danielle Antalffy

working to for say we’d so to taking guys. and excited And go, it’s you. with Mike, afternoon a sad wanted good see been question. I’m you and the Hi, Thanks to much pleasure you just

should of XXXX hoping A I for have little that when more question you access point, XX% you I market in covered Medicare have said of could expect you entering that B now Medicaid, think you and previously, you’ve mentioned you didn’t are incremental so prepared the and to you patients? so we for how coverage have got much say color versus only should XXXX a coverage at Shacey, on Medicare access bit of but access of the lives, to the quick remainder actual So complete give of have this Medicaid the you half and third on point remarks, your for

Shacey Petrovic

Sure.

exception the helping think about we, XXXX. we with to covered of things, we a of actually and essentially patients were that recognized We we lot a Omnipod. Danielle, that process, to then having choice through steer we made So, help when process one Medicare of that people strategic we through thousands plans negotiating and patients Medicare, all providers success, two the help we’ve recognize also could in

integrity in to market, the to established because made we seeing decision really for with be avenues our we fewer order get access providers able so, And other the price strategic to people Medicare. these are in maintain coverage to

through of every So, access covered we And Omnipod to have we actually feel process the happens necessarily lives great patients reflect know landed. I third about is thing that Medicare those remember And many a channels. year. don’t to where how that Medicare other this

so kind that the August, so, of And back bigger that going payers, at is is another final that table September starting at Medicaid able for timeframe the have of say to would again be versus I us to then we’ll opportunity thing bite Medicare. the event. be And we’re the apple these all with

this one see real translating was we’re something important to of to there continue we coverage that expect to grow covered-lives Medicare so obviously a that’s Medicaid that us XX% a where towards Medicaid, population pathway And progress, is the our towards we a large to was pediatric or that very and look exciting end to is it through that, thereabouts. as So, ‘XX. at there continue grow thing we that into strategically is to

Danielle Antalffy

Got it.

is to in in business on higher Pod And clarification that in that on year, this million not it in me, you like of to the lot it selling is but is entirely the correctly first I impact in $XX months, total sounds or in mode to because said, you weeks. probably understand, you will so, us it said, quick confuse if be from bit excuse Mike, think that few Mike, into the I QX. also here you a possible? Can that little assume commentary, I model from headwind like one be understand in DASH. but throughout It the of safe you point headwind that go some in the the of in helpful. is to a understand help majority heard volatility the That’s QX offset Okay. happen shift prices going drive that’s expect to the the full I mostly quarters PDM, coming launch going the going sounds

Michael Levitz

on spot you’re Danielle. No,

spread you’re roughly talking million as as to year evenly a number the an $XX just $X quarter. through example, if million a the about basically $X So, full-year that so million you

because pharmacy channel move both you well the And see who here even we’ve And to new yes, seeing Shacey the you that be full gets so, with offset more momentum in that DASH as pharmacy weeks. into both of into otherwise. described as add the users the with the expect impact, when move or moving the channel, as Omnipod coming into would users, QX DASH, existing where pharmacy been it and great to people date. is timeline DASH It’s then release would to

And help the so that think described timeline it. will reasonable. you is also again, I offset But

Danielle Antalffy

Perfect. Thanks, guys. so much

Michael Levitz

you, Danielle. Thank

Operator

you. Thank

question next from line of the or Our Marcus from comment Robbie JPMorgan. comes

line open. is Your

Robbie Marcus

CEO the new the on for congrats Hi, good transition since you in and in the Insulet CFO thanks role off, at maybe role. Shacey and to mantra you’re start CEO the question the role in quarter. for

think guidance XXXX some give the us should XXXX, You could are guidance you how maybe in set the we some about to here? that on how for considerations and thoughts of relative

Shacey Petrovic

Sure.

Wayde to very similar I process. we for setting XXXX, did XXXX. involved that in path we think were and I Mike say will ultimately, guidance took for both a as

where feel good And about we landed. we so,

really cut I range out needs XX also to to we the in think, the be here look months. if it, to next you play anyway mentioned I to recognizes XX% want talk attractive, over February just XX% we that it what but you and are about as at thoughtful,

the do, ahead acknowledge reflected we about a lot there’s just opportunities also excited We business. to our in European but that’s range, are the really of growth us where seven into months

So, we a great learning, there. are deal

product. a new launching We’re

significant We’re implementing through business and driving we’re manufacturing. channel U.S. pharmacy a the

So, being asked steam. and there’s and all sustainability. the but of that things the lot for profitability on long-term business drive a execution important by these is counted and are long-term And, really growth of that

well, just will executing XX% goes is we’re So, at a it it growth, if goes be that, growth. very well and recognizing we if well, that’s do what it will XX% be

Robbie Marcus

just as Okay, And a great. follow-up.

Danielle on to flat because international can the us great quarter looks and first the year, cadence is a maybe year-over-year. U.S. It guidance Drug little at pretty I’ll, First, working look you looks I was sentiment, with on you’d Mike, trend but it, bit through give look Mike. the Delivery number healthy, growth forward and

just help quarter just back think that’s then through considerations, us year, cadence the maybe the assuming gross any to of for the, I’m you reasons different on the touch could part the year? So and margin in quarter about the if Thanks. slowdown,

Michael Levitz

Sure. Thank you, Robbie.

payors a terms believe repeat won’t in the of good the I’ve healthy for of obviously. and very to just really gross of what very discussed year bit the the to also got which for becomes of which tailwind, I dynamics pay-as-you-go good we but headwind that questions. we playing So, is us. we’ve very, a there, in move got the said impact different the margin, model, a cadence patients, couple and is out initially a already We’ve few

the of materialize is and the and Europe tremendous. in XX% to uplift without what’s customer, impact our growth international have just having the on and end cadence that going a you are revenue in side, with terms on we In in an absolutely ASPs secured thrilled

is in the half normalized second And so was the and same in growth there. it in Shacey the existing difference our in half, the And that cadence described at a time year. there’s as more last first then, Europe markets so

the Delivery what we the throughout going consistent to year roughly be do to this expect we of is tried terms In is historically. we’ve what Drug

always vast but a Drug informs the we not forecast Amgen from have successful, Delivery. are our do of longer-term that We majority

try we reduced even we with Amgen as with working So, and much volatility. out just can as

margin, to flat do about in gross we had earlier, the said XX% of this terms expect year we for the at In be that tremendous as gross result I XXXX. margin

thrilled that. about So, is the cadence we’re different. But

are we manufacturing do So, the to to impact numbers U.S. shortly, launched quarter. the the see the first that that we in as schedule really through than remainder first the year the of would quarter, you on quarter and you assuming in second in more going

there up with prior the to take of the said where I’ve in trajectory I consistent to the fact for essentially here period going you in as we margin So, last thrilled Shacey talk have expect we’ve for are and a costs two Acton. charges going ramp we you accounting first it now been would that to be quarter then the the manufacturing new But are are ramp described comments, to couple as about as quarters. in lines and we

two we U.S. so, are from probably to gross to going And manufacturing. to in margin a have points pullback of three move points this

that the However, operations team both offsets that that. by China doing I the is in that’s and offset in part earlier, otherwise were just tremendous as other said work

I margin. helps gross the on think that some So, all all, in illustrate, cadence for year of the here

Robbie Marcus

so Thanks much.

Operator

you. Thank

J.P. Piper or comes comment from McKim Our the line Jaffray. of next question from

line is Your open.

J.P. McKim

the Ipump? obtaining that? for I towards Hi, the good first on on Can the why? for control? take strategy guess ace of need what’s quicker And ask to question. control I about ask and your Thanks wanted you or taking well getting to move just Omnipod as phone to the As afternoon. wait you Horizon do phone to straight just

Shacey Petrovic

Sure, J.P.

of terms see it’s in just so, And moves making agency think I these the great support pump, the interoperability. to to

establish think and it’s example we as plans have how work been pool issues our do expect innovation so find to as great We we’ve horizon to I but agency a market. about vision DASH think is special controls and for take some time they I controls helpful, it certainly quite just the with more we and don’t and with bring etcetera. really talking any to really in the discussions helping innovation been to agency interoperability doesn’t see for special that change pathways of but advantage pathway, of only to the the

I that. we’re great about So great us, news community, very news for for positive the think

and horizon. than of program. more part and made move include we But it’s it quickly through of and work all as could phone we, just our development as human factors a phone-control control clinical we’re of work horizon going the terms to lot of that testing In sense to

of to to not to Horizon, we is be but expect we the move other that’s work with Galaxy end story and fully starting Samsung well. the that with phone So control, platforms will as underway launch

So exciting is we should remember next of half very the horizon year. just and second

and corner launch. we’re the gearing around great up a right it’s for So, product

J.P. McKim

of half XXXX Shacey, margins kind targets, Okay. you’ve kind of helpful. maybe you And carrying a back mean walked flat you really, your then of just OpEx XX% I on but loaded today these margins take when of lot growth gross one comments the more, XX% kind margin. strategically That’s into this operating you of mid-teens and

it that you million and So, the as you selling smart how pens change, you M&A in those cash targets then CEO what anything for or about looking for XXX getting are anything got at CGM just are comfortable there company about into or differently?

Shacey Petrovic

Yes.

to you that the the said, view we finishing tied quarter main loaded margin. half somewhere this then and back would because expand I’ll unlock back I to to so the finishing as are speak our to implement I really make manufacturing don’t gross gross to making our progress that above XX%, the it’s on comment is order ability think further step great strategy XX% to are XXXX here front. We take those So, targets it biggest year we lever so And, close that in margin. planned is always as a

I completely heading into be plan, we view – exactly really to I expected is this as was back the so… and So, as don’t loaded where year, this part and of it

Michael Levitz

were is to get idea gross out so of in are were we operating would comments that we growth. for Then QX This not an Look, margin strong. at going in I could XXXX were exactly future saw as periods play tomorrow. planned we U.S. QX, Shacey was margins to the and of terms very yes, how just be. investing this add margin. to robust we significant this get is where if we to J.P. you believe we a mean, for always we I of in like targets, outlook, previous said this double-digit be manufacturing if strong And XX% we, can the this the go on what the had we operating of Mike. and ramp we’ve

exactly operating operator value. like So, product. really I want investments these and point, really business our be from think believe it innovation the where standpoint the and do targeted can investments, drive we we’re now we’ve what which the gross channel, pharmacy we’re across to things driving very the this And leverage differentiates broader positioned We revenue growth, margin demonstrated and the profitability just rest in shareholder really already honestly, the pharmacy business. of channel, had which we making

Shacey Petrovic

establishing year, And my change and believe can that not going and as top anybody short growth maybe on just are what we so growth the we laying out we this strategy, line shared. at you to unlock is last see those but fully with two the in targets that our else’s comments are really there and that’s targets much as Pat these top arm-in-arm we and line I was deliver opportunities

Operator

Thank you.

line of from the comes Jayson Bedford from or James. Our comment Raymond next question

Your is line open.

Jayson Bedford

evening. Thanks good and

for Just questions me. of a couple

You on have through mentioned pleased and access pharmacy? DASH, are that you you of with coverage are coverage comment lives what for percent under the the number can of the those

Shacey Petrovic

for lives covered million $XXX about have we Yes, Sure. DASH now.

release. ahead in you that in about going we bit business so basis. and an little position a on grow. like today to think give a expect already report of where to launch ongoing we’re is to actually our market right, on some we to full don’t XX% strong and that of channel I pharmacy But be just visibility expected the on to we’re feel we to So that

the of lives the access all so and look covered expect from you to grow we at we third kind where that’s position that If lives through are about now a of right and year. covered Omnipod

Jayson Bedford

people full situation that launch DASH today launch you that a won’t Omnipod have because Is of though new to that reimbursement? there DASH a access of when

Shacey Petrovic

we because right, the pharmacy that’s Yes, channel. into move are leveraging DASH to

business why I limitations so establish And do as as mean that. some can is there a to coverage the pharmacy to be part if because will DASH they patient to to access able soon terms gets really benefit DASH. of pay-as-you-go the the for in so convert reimbursement of been reason isn’t model that of they choose we’ve there DASH

access primary today is problem, don’t the is they the we see through pharmacy very people market So, have channel it they convert once to And kind and for focus being really of for of waiting etcetera. quickly access access team DASH. our that a expand can’t

Operator

you. Thank

Wuensch comes comment BMO. or from question line of the next Our from Joanne

is open. line Your

Joanne Wuensch

hear me okay? you Can

Shacey Petrovic

Yes.

Joanne Wuensch

margins. the for Pharmacy, or that question. that Terrific. I about Is like where something It Horizon Thank we’ve to taking [indiscernible] sort there factors? on X you the opportunity gross talk you’re and understand the there we’re really the things something just really which key wish missing like, Direct, of U.S. much feels had is OUS you or we so is of – four around we the just four sort it these focused

Shacey Petrovic

you long-term didn’t one value – a important that U.S. you the just do manufacturing. thing I is the driver mention, think for company which really is

obviously line little our to creating capacity costs has to and I bit us in increase the U.S. but drive talked capacity, give and think that, second we quality expect that that and redundancy. the about are needed we down So, fact where establishing now a much also much fully we ability to this the it,

position and And in as so a we’re massive value that of the is that kind strengthening a company. driver of

So, more the it’s that for deliver to and thrilled on the that what is I be promise could going about investment not company.

Joanne Wuensch

just Drug all little was it in a on think it looks a it’s we XXXX, really just can but thoughts one? bit it’s much, that spend XXXX moment I in like heavier when declining I Delivery, on little question, mean a at about don’t any than second And bit know we heavier, too faster,

Shacey Petrovic

opportunity. think Drug for then guidance forecast growth guidance. range is an really exciting the always based Delivery We Yes, our Amgen’s Drug into production our factored as I mean, view what’s the still and that’s I long-term Delivery planning, primarily on into so and

is example Amgen the and can the that’s Amgen. be just but done, also this competitive market obviously changes it’s of from is partnership strong I very reality think a our reflected forecast the and in what as great

Michael Levitz

add now of we Delivery our just are – but than would I And not Drug the is obviously forecast down, less when thrilled XX% come revenue. it’s

have And the of part us, rapidly. so impact so business of of it because our growing business on all really much so parts our that is are didn’t meaningful smaller other a and it an

Operator

you. Thank

the question or from Our comment line next of comes from Margaret William Kaczor Blair.

Your line is open.

Unidentified Analyst

are presumably we’re wanted question. for through Everyone, and benefits DME better for pharmacy follow-up and thanks to much I similar scripts, often, physicians channel, taking of better then pharmacy, patients, more they is is, since guys more that, I are are utilization? is seeing the between experiences, who well Omnipod resulting And to I going and now easy more a Brandon the is you it – in early by any I are other you talking competitive the seeing through for utilization going than passes I’m process in notable off pharmacy easier reordering and an such differences to kind recommend This pumps? your going to mean, as in Margaret. start patients compliance saying about just in easier this that guess, am

Shacey Petrovic

vision customer definitely physician. this and both those we believe utilization, outside I provide channel. a know that I the utilization but is think our the to will pharmacy for experience of described substantively, think questions. that for increase really don’t necessarily we think are channel great And you Brandon, better I going the patient

for don’t feedback And be and feedback bit type and market terms to we in experience so very the think release channel the specific yet feedback positive a I you early because from have it’s I limited in will but of patient looking the feedback give in the early been days, little pharmacy. physician of that has patient

Michael Levitz

other the would in Yes, just being our – add it so definitely received. is well acceleration existing are the thing pharmacy, it’s is seeing that I with product we only

Unidentified Analyst

international a of increase should on understand remind outside any XXXX as think are ASP plans markets follow-up of quick in just trying me expand we to well? remind Thank then new there side. if how international Europe, blended And the of you’re international outside in, if And Thanks. I into you all is market? to Omnipod there Could us you. other guess, in or of it. a that many about the Got markets

Shacey Petrovic

Mike sure I’m add can some and start I’ll color.

we or of XX are Europe I So substance. markets in really today think total, of in in a handful X any X countries

in in the are United States Canada Israel. We are we and and

the It’s So, to it’s really the terminate about it footprint. made why decision so reasons our this of investment we our expand a one limited because ability legacy unlocks pretty global we’re in to to that markets. distributorship, now new excited geographic

the that contemplates we’re in is range in lower mention and further want our now the XXXX, end, you guidance of so existing research on in the move – thing the pressures in And most we only the factored that’s guidance is prioritizing the – contemplate into and XXXX that ASPs, to markets that doing attractive mentioned into. markets In really may international growing really and pricing categorizing guidance. I’ll so does the our process

Michael Levitz

question because you the sometimes I confused. that just And glad would get add you’ll brought up I’m

international uplift confusing. sometimes international the So, going in Europe that us applies XX% of layer roughly there our on Europe, of in XX% rest that doesn’t uplift to to represents ASP and the by apply replacing XX% the Europe, it business that’s revenues one so and direct

So, thank question. the you for

Unidentified Analyst

Okay.

Operator

Thank you.

We have more question. time for one

Baird. from for question from this final line Jeff the evening Our of comes Johnson

is open. Your line

Jeff Johnson

guys, Hey you okay? afternoon. Can me good hear

Shacey Petrovic

Yes, Jeff.

Jeff Johnson

it anything Have that’s don’t I’ve late developed now of heard few last levels, in FDA in that? XXXX since half the comments, you’ve last over there, the of change heard the half but Great. any launch XXXX? of XXXX, pathway kind of Horizon I’ve to about had you confidence on we and from visibility just it talked increased Shacey, I any months second second mentioned kind want a couple your times over-read

Shacey Petrovic

the the I just have think devices lot program, collaboration it’s we the agency. is breakthrough a this about we thing frankly, with – great of that

to through lot sure around development a and talking more been most we’ve the have clinical we bit so the that. efficient that market, so making And a clarity pathway plan effective and

the it no, nothing’s so so, we’re and feel guidance, timeline just [indiscernible] making really in development And be about good I progress the changed earlier. – that both but the plan. clinical will on our on that our very front I

Jeff Johnson

headwind a then and Thank then pods outside Alright, and kind follow-up do similar we market. just of way that’s you. the to question, just about And conversion the think DASH priced on international an might on international the the helpful. initially we it same or need When uplift will the – U.S.? on in still market, see work higher

Shacey Petrovic

question, Great, and Jeff. that’s a really good

markets. back international them demoed us. to of just our system demand, know of We right lot last the a to relates with launch not it don’t we’re the in a model, wanted evaluation ATTD, So, all none in give I process of we of would work the week there’s as clear and headwind It’s similar to so, go-to-market think strategy. to of that doing to at the we European include fact, DASH I kind for me understand that physicians will

to late So, more hard we of make be Europe, would launch to across can working Europe. product ‘XX, that we very in early XXXX are a I that expect launch sure that

Operator

Thank you.

our extend can session. Q&A we So,

question or from comes next our the So, Ravi from comment of line Misra Berenberg.

Your line is open.

Ravi Misra

thank I of taking and question. couple future. – in a just to for congratulations clarity you Hi, luck the good the wanted Mike get and

over that if the as I I then to Just went should profitability by G&A, those think calls? profitability a help it kind you mean between pertains the the market apologize Thanks. what Can secondly on actually little us of wanted peg is? just we S&M And just think targets, clarity that you in commentary, XXXX on you Shacey, switching about how above been and what get down long-term. said already, just bit to OpEx you market

Shacey Petrovic

Great.

Michael Levitz

I’m and Well, please fill happy to Shacey start obviously in.

said, So, in of profitability, ‘XX above as the market mid-teens. terms we’re that really Shacey as of targets viewing

kind Now of when set XXXX market, was XXXX, nobody the we what’s target that delivering profitability. that diabetes for in – market

that setting that That try – profit in decent company. And reflected felt that business. is schedule delivered the that that This not as to the in company you so is positive target I of what a could would position. year story that very and the a something now, like net appropriate make given first ahead said We been of really for the could – is target and appropriate do positions we we we’ve we the the and had really delivered income now net this of said this targets we as is just really view loss EBIT income. reasonable you for we XXXX our end before mid-teens. for positive full-year thought well And and was us

the and development work really that would to working over include on and leverage the the of to, the is year would time is piece sales – we’re OpEx I’ll terms just business. the the Shacey a that of there we’re innovation which ‘XX so In increase of from there’s my amount largest include we’re benefit driving good guidance and which could said move will now from that half in reiterate on. as that just second pharmacy, Apart really the away and but speak comment, marketing business, in a across earlier Shacey Horizon the in and across us, and second G&A, the of

Shacey Petrovic

be to Yes, since to to effectively you capabilities investment pharmacy marketing, patients channel this able improve be just to the to there move an really in and and DME year able to our the channel specifically mentioned channel. the from is pharmacy sales

OpEx. is we believe it’s out of us it’s So, that look is investment over And Horizon, – as a for a investment we attractive that’s is reasons. that a – in worthy the channel an investment then because not one-time captured for some number investment that more of complete

Ravi Misra

the patient per less the higher channel kind – is just the that out-years? a I just can lead should follow-up there, it in seek And is mean, lead dynamic just may a to there, should if of ROI profit that, service should to that on that to because, so per pharmacy case patient expensive that I the leverage patient

Michael Levitz

can I’ll then comment Shacey in. and jump

made and work and in it’s revenue don’t value the to work for to different less the less beneficial that’s is, and on physicians be over cost less There’s past there – the the constitutes is in channel customer for said so pricing a really reasons of just users, side, us pharmacy only work the and Shacey comment be we think we’ve work, the expect lower to it’s cost. for time. one the that less I just it’s work the different being the

And so real. right very that doesn’t but is it materialize away,

Shacey Petrovic

Yes, right, no, that’s you captured.

Operator

you. Thank

from Oppenheimer from or the of Our comes question line and Company. next Steven comment Lichtman

open. line is Your

Steven Lichtman

think XX me squeezing today could can will you guidance, exit Shacey with going mix of on your that what was provide as pharmacy if you XXXX? for provide specifically. commentary to ramp through I if your Any XX% of assuming over base, about I’ll the be guys installed wondering one, pharmacy within you next the or mentioned, channel be just stick XX it’s – should you months how that mix in. about can’t U.S. the I you’re you Thank you share we we months? thinking

Shacey Petrovic

Yes, I it’s question. a great think

I So today, a think mentioned I about covered it’s million of – position, lives third coverage about – XXX think said I from a about you covered DASH. were If we it’s so lives, where somewhere a have we to access around third are XX%, XX%. if just

all think expect track we if We how guardrails about to to that’s and year. from would them batting to average ramp we this as you move might that So, but convert were down have the don’t XX% of on all, kind XX%. able them XXX% that,

Steven Lichtman

Okay, great. Thanks, Shacey.

Shacey Petrovic

Sure.

Operator

you. Thank

Our or the comment Pasquale Chris from from of next question line Guggenheim. comes

Your line open. is

Chris Pasquale

[ph] million was PDM on a U.S. about, One what revenue to the to of DASH, quarter it’s $X your estimate million Thanks. a you about XXXX. $X we talked third follow-up headwind does in

usually Just numbers the set explicit baseline, is that don’t a guys give right ballpark? in you to there, I but know

Michael Levitz

PDM what the about to we’ve Hi, related of we We don’t DASH What that really – though launch foregone talked break is is, pay-as-you-go revenue say model. would it’s I and Mike. the Yes. Chris, out. don’t in

We’re be still Omnipod globally. existing selling going to our

revenue little in fact, And a to in to the in the model started of XXXX. move so PDM here we it’s in pay-as-you-go not going even like year. And, a zero we’re bit

give we break a a people we’re I the just So, total out but that impact. – rough that wanted number, to on could get number not of so a don’t sense

Chris Pasquale

operating Okay. OpEx two in we spending Any overall the fourth jump expect you, during growth expected rates than to And big how quarter XX% particular. little XXXX? on was lines R&D then in the color Mike, you maybe just mix different had those the the compare growth in one expenses follow-up for of to of would

Michael Levitz

that’s going that the really is Absolutely. And, and work and call, that’s DASH development in bit happened. the the And which away expect fact, did now clinical and ramp related the in to really exactly development expenses of on QX international to little this was quarter it’s built to XXXX what it’s that’s Horizon, fourth I on which is the and a we it finishing the to we are operating There’s work a spoke the up Horizon. what specifically now going be on when into work specifically R&D. and work with that most work year so in is in

grow globally. and really really in number the because the innovation that That’s one see of from OpEx. we I the expect it to than rest the value is spending of R&D faster So, driver growth of this would

move some specific really down drive to will leverage sure marketing to real believe operating be and these a growth come operations the I making initiatives across we as have And say, the OpEx, across cost and time, things, will pharmacy there as value. We are and these support fund across will – to of do because the company. in infrastructure over channel we company, that that the driving the to we sales that, is

Operator

Thank you.

from comes of Our from next line or Taylor question UBS. comment Matt the

is line open. Your

Matt Taylor

thank you the for question. Hi, taking

wanted I to things. So, two ask

Drug here still is, much just potentially there Analyst bigger opportunities. years the I The core over understand on is pivoted about the with this being pump first with a couple one that Delivery you think talked time want about you this in more year. Is a case Day, opportunities ask have or business? of the you bigger insulin – was pressure just to business I we you’d at What your ago there some

Shacey Petrovic

another at of Insulet need that what When And guess, think both the said, true those. have look champagne horizon challenges of for Amgen you problems just we growth, – so hit them in we I XXXX as have that time I targets, are it. we do. we I just depending determine we is, think pursue on the always to big, don’t one terms could going many are different I call here that at we we it’s that opportunities so to important the

stage much Delivery, it’s stuff when activity was with some asset had had much failure so that but at so Drug bandwidth-intensive really incredibly more a we we was of was that and high some commercial of look And reliable, the early that rate. underway,

so a at of Neulasta, these commercially these available like you for if you any or And even programs at be even look look concentrated insulin programs X-year molecules. could

frankly, And right we full development business. longer-term diabetes growth a and our the the growing hands longer-term so have Horizon, happily now it’s opportunity just

diabetes is haven’t year, some look XX% to we growing exciting even out XX% If growth Delivery, delivered we you on future. catalysts the this take Drug really as and over

do we’re opportunity. and a focus Drug selective it think we is. programs do view activity that’s on but our have as more going I little where still Delivery, So, the in a We being bit about longer-term

Matt Taylor

are. was that I picture on a that of And wondering you so those want the great follow-up one on one fourth helped other congrats it’s you of fourth in some color to quarter bit of working had quarter. could you. know just great been years, in ones or – year? then ones what said And which a helped big that’s little Okay. the during And the wins all sort or back help anything Mike, and we us did if of pacing comments, give go on just those few specifically could with and I you your to this access

Michael Levitz

question, Matt. of talked here you, exception about see we’ve really all, to better process the wins, answer one on were be to wins And able started real may and the with we but some the beneficial. was of that Shacey access to is thank that that Medicare, that before that Well, early first starting things in and will say kick I in

had it by call wins significant wins, we’ve we’ve tell some Medicaid, wins out had pretty Medicare, we’ve in – we’ve I them, had in so and I And can’t wins had but wins can’t we’ve name, commercially. had

the thought Medicare I kick say in some of that ‘XX things early. come in, we’re actually as And we going on have to

really want that access our And reflects when so growth this the we’re customer in our just product, it it’s – is base that this do just starts, in have fact to I mean the And seeing fantastic. new product. they people

Operator

Thank you.

or question Our Northland comment line Suraj final the comes of from from Kalia Securities.

Your line is open.

Suraj Kalia

for everyone. me squeezing Hey, good you afternoon, Thank in.

So first X.X been configured and receive – designation? they Can they with you, me if high the a your working asked foremost, me you best very Mike, in been wish let typical it’s future an endeavors. with Omnipod forgive pleasure others. if the questions Shacey, by have be Libre and

Shacey Petrovic

the down a road. it FDA thing in integration were certainly if about Horizon of reach very the clinical could for a that’s beautiful pathway that sensor special then Yes, they easy their example created to be to path this controls able has

Suraj Kalia

my you time you pumps of FY ahead Horizon. are most from in Got guys XX% do What to at to themes you was this at of If and as questions. and are know, one taking the the view? you I look How for loop XX% system running Thank closed-loop it. the beyond, And one differentiates time going another? you be look ‘XX finally, closed Shacey, at ATT obviously, range. on

Shacey Petrovic

Sure, great two question. Suraj. I’ll just And say think I a it’s things.

First on data the some data other very in data. at data more is is of looking is all, and ways, these real population, looking varying all systems well-controlled at collected world

to be think I about So, just have all of we skeptical the performance. variety of

do elegantly I terms terms the time more think the how all going translates to user, the come and the to when pump the time we of about real and experience system look closed interface in more the spend of of that and at that the and sensor work they the differentiators for time in range, how on range. together, more because and these together the of loop user better to have pieces it’s in the that system, in easily work they’re

experience so MDI mean, simple And as and I that’s so designing come for well system could because used users, to on the system. down translates we been be I it’s children, laser-focused the why experience, on that user for to interface a think going the customer just how as focused, the have user

Operator

the back in queue conference showing Thank you. no the further I now to questions Petrovic. Shacey time. like would this turn I’m at to

Shacey Petrovic

forward us want set be XXXX today. will had working growth have of the across joining for people Thanks, of XXXX looking and we’re with we’re lives exciting important globe milestones I remarkable and progress. more remarkable Insulet speaking thank to diabetes. Great. a Thank and quarter future. evening. another to team year an you all the you up great to the continued a even of again improve all and for our next with on Insulet

Operator

and and for Thank Ladies this today’s wonderful gentlemen, have a participation your day. concludes conference. you

may disconnect. You all

Insulet (PODD) 26 Feb 192018 Q4 Earnings call transcript